MA55205A - Formulations injectables prêtes à l'emploi - Google Patents

Formulations injectables prêtes à l'emploi

Info

Publication number
MA55205A
MA55205A MA055205A MA55205A MA55205A MA 55205 A MA55205 A MA 55205A MA 055205 A MA055205 A MA 055205A MA 55205 A MA55205 A MA 55205A MA 55205 A MA55205 A MA 55205A
Authority
MA
Morocco
Prior art keywords
ready
injectable formulations
use injectable
formulations
injectable
Prior art date
Application number
MA055205A
Other languages
English (en)
Inventor
Todd P Foster
Vijaya Bharti Joshi
Laibin Luo
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of MA55205A publication Critical patent/MA55205A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA055205A 2019-03-06 2020-03-05 Formulations injectables prêtes à l'emploi MA55205A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962814440P 2019-03-06 2019-03-06

Publications (1)

Publication Number Publication Date
MA55205A true MA55205A (fr) 2022-01-12

Family

ID=70009447

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055205A MA55205A (fr) 2019-03-06 2020-03-05 Formulations injectables prêtes à l'emploi

Country Status (11)

Country Link
US (1) US20220125798A1 (fr)
EP (1) EP3934618A1 (fr)
JP (1) JP7323630B2 (fr)
AU (1) AU2020232306B2 (fr)
BR (1) BR112021017536A2 (fr)
CA (1) CA3132159C (fr)
IL (1) IL285520A (fr)
MA (1) MA55205A (fr)
MX (1) MX2021010689A (fr)
WO (1) WO2020181024A1 (fr)
ZA (1) ZA202105883B (fr)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2557615C2 (de) 1975-12-20 1985-08-14 Bayer Ag, 5090 Leverkusen Neue Niclosamid-Suspensionsformulierungen
CN1517090A (zh) * 2003-01-20 2004-08-04 王玉万 含抗菌药物的兽用混悬注射剂或乳剂
US20040214753A1 (en) 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
CN1569000A (zh) * 2003-07-16 2005-01-26 王玉万 含头孢菌素的速效并长效注射剂
WO2010059717A2 (fr) * 2008-11-19 2010-05-27 Merial Limited Formulations comprenant du ceftiofur et du kétoprofène ou du ceftiofur et de l'alcool benzylique
KR20140102319A (ko) * 2011-12-23 2014-08-21 바이엘 뉴질랜드 리미티드 항생제 제형
WO2013173687A1 (fr) 2012-05-18 2013-11-21 Genentech, Inc. Formulations d'anticorps monoclonal à concentration élevée
CN108578362A (zh) * 2018-05-30 2018-09-28 河北维尔利动物药业集团有限公司 一种头孢维星混悬注射液及其制备方法

Also Published As

Publication number Publication date
JP2022523573A (ja) 2022-04-25
JP7323630B2 (ja) 2023-08-08
MX2021010689A (es) 2021-10-01
US20220125798A1 (en) 2022-04-28
EP3934618A1 (fr) 2022-01-12
NZ779449A (en) 2023-11-24
CA3132159A1 (fr) 2020-09-10
IL285520A (en) 2021-09-30
BR112021017536A2 (pt) 2021-11-09
WO2020181024A1 (fr) 2020-09-10
AU2020232306A1 (en) 2021-09-02
ZA202105883B (en) 2023-03-29
KR20210120084A (ko) 2021-10-06
AU2020232306B2 (en) 2023-11-16
CA3132159C (fr) 2023-11-21

Similar Documents

Publication Publication Date Title
MA46696A (fr) Formulations injectables à dose unique prêtes à l'emploi
UA42295S (uk) Комп'ютер
MA54521A (fr) Dérivés d'oxopyridine substitués
UA42369S (uk) Комп'ютер
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
MA55200A (fr) Composés utiles dans la thérapie du vih
MA53280A (fr) Composés utiles dans la thérapie du vih
DK3725355T3 (da) Indpakket præcisionssmurt intermitterende urinkateter klar til brug
ITUA20162350A1 (it) Composizione per decolorare la fibra cheratinica
ITUB20153542A1 (it) Composizione cosmetica ad attivita' idratante
MA47106A (fr) Formulations d'anticorps anti-tnf alpha
MA55205A (fr) Formulations injectables prêtes à l'emploi
DK3840596T3 (da) Sammensætning
MA51009A (fr) Composition de soins buccaux
MA52934A (fr) Composés inhibiteurs de l'oga
MA43764A (fr) Inhibiteur monovalent de l'interaction hutnfr1
DK3908321T3 (da) Farmaceutisk sammensætning
DK3911298T3 (da) Formuleringer
DK3746047T3 (da) Injektionsbar sammensætning
IL271658A (en) New oral formulations of belinostat
DK3752598T3 (da) Allogen sammensætning
MA54237A (fr) Composition attractive de l'espèce delottococcus aberiae
DK3763212T3 (da) Artropoda-afvisende sammensætning
DE202019104765U8 (de) Dentalbürste
MA46568A (fr) Dosage biologique de formulations d'insuline